- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.01. | Anish Patel, COO von Enliven Therapeutics, verkauft Aktien im Wert von 685.868 US-Dollar | - | Investing.com Deutsch | ||
| 31.12.24 | Finanzvorstand von Enliven Therapeutics verkauft Aktien im Wert von 94.474 US-Dollar | 1 | Investing.com Deutsch | ||
| 24.12.24 | Enliven Therapeutics (NASDAQ:ELVN) Trading Down 2.9% - Should You Sell? | 1 | MarketBeat | ||
| 02.12.24 | Enliven Therapeutics CFO Benjamin Hohl verkauft Aktien im Wert von 130.688 US-Dollar | 2 | Investing.com Deutsch | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.11.24 | Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% | 1 | MarketBeat | ||
| 14.11.24 | Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02 | 2 | Seeking Alpha | ||
| 13.11.24 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 115 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains... ► Artikel lesen | |
| 30.10.24 | Enliven Therapeutics CFO Benjamin Hohl verkauft Aktien im Wert von 178.484 US-Dollar | 2 | Investing.com Deutsch | ||
| 30.10.24 | Enliven Therapeutics gets Buy rating, $36 target from Jones Trading | 1 | Investing.com | ||
| 22.10.24 | Wissenschaftlicher Leiter von Enliven Therapeutics verkauft Aktien im Wert von 25.412 US-Dollar | 1 | Investing.com Deutsch | ||
| 22.10.24 | Enliven Therapeutics CEO Kintz verkauft Aktien im Wert von 27.722 US-Dollar | 1 | Investing.com Deutsch | ||
| 22.10.24 | Finanzvorstand von Enliven Therapeutics verkauft Aktien im Wert von 24.422 US-Dollar | 1 | Investing.com Deutsch | ||
| 22.10.24 | Enliven Therapeutics COO Anish Patel verkauft Aktien im Wert von 21.482 US-Dollar | 1 | Investing.com Deutsch | ||
| 18.10.24 | ELVN stock soars to 52-week high, reaching $28.66 | 1 | Investing.com | ||
| 18.10.24 | ELVN-Aktie erreicht 52-Wochen-Hoch bei 28,66 US-Dollar | 1 | Investing.com Deutsch | ||
| 07.10.24 | Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy? | 2 | MarketBeat | ||
| 01.10.24 | Enliven Therapeutics-Aktie behält Outperform-Bewertung von Mizuho nach positiven Studiendaten | 2 | Investing.com Deutsch | ||
| 01.10.24 | Enliven Therapeutics shares maintain Outperform rating from Mizuho with positive trial data | 2 | Investing.com | ||
| 29.09.24 | Enliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia Patients | 3 | RTTNews | ||
| 28.09.24 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia | 2 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,228 | +1,74 % | Valneva: Hohe Immunantwort durch Chikungunya-Impfstoff | Valneva hat neue Phase-3-Daten für den Chikungunya-Impfstoff IXCHIQ veröffentlicht, die eine anhaltend hohe Immunantwort bei Jugendlichen bestätigen. Ein Jahr nach der einmaligen Impfung zeigten Studienteilnehmer... ► Artikel lesen | |
| BIOFRONTERA | 2,585 | 0,00 % | Biofrontera files to sell 5.72M shares of common stock by selling shareholders | ||
| CRISPR THERAPEUTICS | 42,500 | +7,05 % | CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell? | ||
| BLUEBIRD BIO | 7,720 | +2,39 % | bluebird bio Announces 1-for-20 Reverse Stock Split | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock... ► Artikel lesen | |
| AFFIMED | 1,070 | 0,00 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to January 31, 2025.Accordingly... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,254 | -2,98 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,650 | +1,25 % | Denali Therapeutics Inc.: Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial | Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeksOverall, DNL343 was found to be safe... ► Artikel lesen | |
| CELLECTIS | 1,550 | -1,65 % | Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 | UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs - one allogeneic... ► Artikel lesen | |
| AGIOS | 31,600 | +1,94 % | Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0% | ||
| VOYAGER THERAPEUTICS | 4,992 | -4,46 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2024 Financial and Operating Results | - Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data... ► Artikel lesen | |
| UNIQURE | 14,350 | -2,35 % | uniQure Inc.: uniQure Announces Pricing of its Public Offering | LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| SCILEX | 0,431 | 0,00 % | Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c) | PALO ALTO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing... ► Artikel lesen | |
| ENZO BIOCHEM | 0,640 | +3,23 % | Enzo Biochem settles lawsuit over 2023 ransomware attack for $7.5M | ||
| ALLOGENE THERAPEUTICS | 1,920 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and ... | Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of... ► Artikel lesen |
ENLIVEN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 22,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.
